thioridazine has been researched along with Leukemia, Myeloid, Acute in 4 studies
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine." | 2.87 | A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. ( Almakadi, M; Aslostovar, L; Bhatia, M; Boyd, AL; Collins, TJ; Foley, R; Julian, JA; Kim, RB; Leber, B; Leong, DP; Levine, MN; Tirona, RG; Xenocostas, A, 2018) |
| "In pediatric acute myeloid leukemia (AML), intensive chemotherapy and allogeneic hematopoietic stem cell transplantation are the cornerstones of treatment in high-risk cases, with severe late effects and a still high risk of disease recurrence as the main drawbacks." | 1.56 | Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death. ( Benetton, M; Borella, G; Borile, G; Buldini, B; Campello, S; Cogo, P; Da Ros, A; Locatelli, F; Massi, A; Minuzzo, S; Pigazzi, M; Polato, K; Porcù, E; Romagnoli, R; Simonato, M; Simula, L; Tregnago, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tregnago, C | 1 |
| Da Ros, A | 1 |
| Porcù, E | 1 |
| Benetton, M | 1 |
| Simonato, M | 1 |
| Simula, L | 1 |
| Borella, G | 1 |
| Polato, K | 1 |
| Minuzzo, S | 1 |
| Borile, G | 1 |
| Cogo, P | 1 |
| Campello, S | 1 |
| Massi, A | 1 |
| Romagnoli, R | 1 |
| Buldini, B | 1 |
| Locatelli, F | 1 |
| Pigazzi, M | 1 |
| Aslostovar, L | 2 |
| Boyd, AL | 2 |
| Benoit, YD | 1 |
| Di Lu, J | 1 |
| Garcia Rodriguez, JL | 1 |
| Nakanishi, M | 1 |
| Porras, DP | 1 |
| Reid, JC | 1 |
| Mitchell, RR | 1 |
| Leber, B | 3 |
| Xenocostas, A | 3 |
| Foley, R | 3 |
| Bhatia, M | 3 |
| Almakadi, M | 1 |
| Collins, TJ | 2 |
| Leong, DP | 1 |
| Tirona, RG | 1 |
| Kim, RB | 1 |
| Julian, JA | 1 |
| Levine, MN | 1 |
| Sachlos, E | 1 |
| Risueño, RM | 1 |
| Laronde, S | 1 |
| Shapovalova, Z | 1 |
| Lee, JH | 1 |
| Russell, J | 1 |
| Malig, M | 1 |
| McNicol, JD | 1 |
| Fiebig-Comyn, A | 1 |
| Graham, M | 1 |
| Levadoux-Martin, M | 1 |
| Lee, JB | 1 |
| Giacomelli, AO | 1 |
| Hassell, JA | 1 |
| Fischer-Russell, D | 1 |
| Trus, MR | 1 |
| Brown, ED | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease[NCT02096289] | Phase 1 | 13 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thioridazine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dopamine D2 Receptor Antagonists; | 2018 |
3 other studies available for thioridazine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death.
Topics: Calcium; Cell Death; Child; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; My | 2020 |
Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients.
Topics: Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Receptors, Dopamine; Signal | 2021 |
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Dopamine Antagonists; Drug Screening Assays, Antitumor; | 2012 |